"10.1371_journal.pone.0007258","plos one","2009-09-30T00:00:00Z","Patrice Dubreuil; Sébastien Letard; Marco Ciufolini; Laurent Gros; Martine Humbert; Nathalie Castéran; Laurence Borge; Bérengère Hajem; Anne Lermet; Wolfgang Sippl; Edwige Voisset; Michel Arock; Christian Auclair; Phillip S Leventhal; Colin D Mansfield; Alain Moussy; Olivier Hermine","INSERM, U891, Centre de Recherche en Cancérologie de Marseille, Signalisation, Hematopoiesis and Mechanisms of Oncogenesis, Centre de référence des mastocytoses, Marseille, France; Institut Paoli-Calmettes, Marseille, France; Univ Méditerranée, Marseille, France; AB Science SA, Paris, France; University of British Columbia, Department of Chemistry, Vancouver, British Columbia, Canada; Institute of Pharmaceutical Chemistry, Martin-Luther-Universität, Halle, Wittenberg, Germany; Laboratory of Oncology and Molecular Pharmacology, CNRS, UMR 8113, Ecole Normale Supérieure de Cachan, Cachan, France; Service dHematologie, CNRS, UMR 8147, Centre de référence des mastocytoses, Université Paris V René Descartes, Hôpital Necker, Paris, France","Conceived and designed the experiments: PD MC LG MH AL MA CA OH. Performed the experiments: PD SL MC LG MH NC LB BH AL WS EV MA CA. Analyzed the data: PD MC LG MH NC BH AL WS MA CA PL CM AM OH. Wrote the paper: PD LG PL CM AM OH.","This study was financially supported by AB Science, S.A., Paris, France. AB Science is the proprietary holder of masitinib. Masitinib is under clinical development by AB Science. P.D., S.L., M.C., L.G., M.H., N.C., B.H., A.L., C.A., P.S.L., C.D.M. and A.M. are employees of the study sponsor, AB Science. M.C., M.A. and O.H. are scientific advisors to the study sponsor, AB Science. P.D., M.C., L.G., M.H., A.L., A.M. and O.H. are shareholders of the study sponsor, AB Science. M.C., A.L. and A.M. are applicants on numerous patents pertaining to masitinib.","2009","09","Patrice Dubreuil","PD",17,TRUE,8,13,14,6,TRUE,TRUE,FALSE,0,NA,FALSE
